enfuvirtide

Action and Spectrum

Drug Interaction

Adverse Reaction

Frequency defined:   

>10%: 

Fatigue  

Diarrhea 

Nausea 

Cyst at the injection site 

Injection site infections  

1% to 10%: 

Folliculitis 

Weight loss 

Abdominal pain 

Xerostomia 

Pancreatitis 

Anorexia  

Eosinophilia  

Infection  

Herpes simplex infection  

Myalgia  

Flu-like symptoms   

Post-marketing<1%: 

Amyloidosis 

Anxiety  

Constipation 

Nausea  

Skin rash 

Vomiting 

Respiratory Distress  

Renal insufficiency 

Thrombocytopenia  

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pregnancy consideration: Enfuvirtide can transfer into minimal to low amounts across the human placenta. 

Lactation: Enfuvirtide excretion in breast milk is not known.  

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women. 
• Category N: There is no data available for the drug under this category. 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: Enfuvirtide  

Pronunciation: enfuvirtide  

Why do we use Enfuvirtide? 

It is used to treat viral infections such as HIV infection.